To Get More Information on Biosimilars Market - Request Sample Report
The Biosimilars Market Size was valued at USD 29.51 Billion in 2023 and is expected to reach USD 127.92 Billion By 2032 and grow at a CAGR of 17.7% over the forecast period of 2024-2032.
The biosimilars market has blossomed with the increasing demand for affordable alternatives to biological therapy. Most of the biologic drugs that are now coming off patent in the U.S. have created huge interest among manufacturers to start working on biosimilars that are as efficacious and potent as the original biologics. The adoption of biosimilars has been slow so far in the U.S. because of patent disputes, reimbursement complexities, and physician/patient acceptance issues; however, the market in the U.S. is expected to grow at a rapid pace in the coming years. A total of 35 biosimilars have been approved by the FDA up to April 2022. Of these, 21 are commercially available. The number of biosimilars approved reached 40 as of December 2022, of which 25 have already been launched.
Other chronic diseases, including cancer and autoimmune disorders, are on the rise, representing one of the strong platforms for further acceptance of biosimilars that provide clinical equivalence at significantly lower prices. For example, biosimilars like Ziextenzo, which treat neutropenia, are around 37% cheaper compared to their biologic counterparts. While major biologic blockbusters are set to lose patent protection, the use of some USD 60 billion worth of annual peak sales will increasingly become vulnerable to biosimilar competition and start new opportunities for market players. Among them, such key launches as Samsung Bioepis and Merck's trastuzumab biosimilar, Ontruzant, began the wave of biosimilar entries to the U.S. market.
Though great promise has been shown by biosimilars, manufacturing complexities are a huge barrier. Biosimilars need to have fuller clinical trials and post-approval safety monitoring as compared to original biologics. Biggies like Amgen have a competitive advantage with such a huge cost run-up of USD 100–250 million for a manufacturing facility and the expertise needed in the production of biologics.
In emerging markets, including Asia Pacific, Latin America, and Middle Eastern markets, which are less demanding in terms of regulation, growth opportunities are considerable as the development of biosimilars can advance. China and India have become developing centers for the research and development of biosimilars, mainly due to lower labor and manufacturing costs. The threat of competition from originator companies launching second-generation biologics or reformulated products hurts the market share of biosimilar companies.
Market Dynamics
Drivers
Development and Launches in Biosimilars
The high growth in the biosimilars market is being driven by the intense focus of major players in the industry on developing and obtaining regulatory approvals for biosimilars. As of December 2022, the U.S. FDA had approved 40 biosimilars, with 25 launched in the U.S. market. Even the COVID-19 pandemic was a temporary roadblock in the approval process as seven new biosimilar approvals were seen in 2022. All of the biosimilars approved in 2022 were based on previously approved reference products, and no completely new reference product had been included. The year was also marked by the approval of four new products, including the first two biosimilars for Lucentis, as well as the FDA's designation of two new interchangeable biosimilars: Rezvoglar, referencing Lantus, and Cimerli, referencing Lucentis.
Although the number of biosimilars approved between 2020 and 2021 decreased slightly, the number of development programs participating in the FDA Biosimilar Development Program has been steadily growing. Today, it is estimated that around 60-70 biosimilars stand somewhere in the pipeline. About half of these should be launched within the next three to four years. This product pipeline continues to expand and is likely to witness a massive increase in the market due to increasing entry levels of biosimilars, with more entering the market providing cheaper alternatives to biologics and thereby increasingly creating competition within the healthcare sector. Biosimilar development continues to shape the market as they continue gaining approvals, allowing expanding access of patients to affordable therapies of biologics.
Restraints
High Costs and Stringent Quality Requirements
The development of biosimilars is complex and expensive, requiring substantial investments, advanced technical expertise, robust clinical trial capabilities, and strict adherence to high-quality standards.
Key Segmentation
by Type:
Monoclonal antibodies contributed 27.4% of the market share in 2023, as monoclonal antibodies found significant applications in a variety of fields, such as oncology, autoimmune diseases, and infectious diseases. There were three main reasons for the leading position: their mechanism of action, high efficacy, and specificity in treatment, and continued advancement in the process of developing it. Granulocyte-Colony Stimulating Factor is growing the fastest because it plays a major role in the management of chemotherapy-induced neutropenia and other related blood disorders. Gaining popularity with more patients diagnosed with cancer and more frequent use of more than one kind of cancer treatment demand for G-CSF hails in this drug which is growing rapidly in the market.
by Application:
Blood disorders possess the highest market share, 37.2% in 2023, due to prevalent diseases like anemia, hemophilia, and other hematological diseases. Advanced treatments currently under development and awareness of the disorders are working to build up the momentum for the latter application area. Oncology diseases have shown the fastest growth rate as a segment, led by an increase in cancers globally, and higher developments in cancer treatment. This has also been seen to progress rapidly due to the growing emphasis on personal medicine and targeted therapies involving new treatments for all types of cancer.
Regional Analysis
North America was the dominant force in the region accounting for 43.2% market share in 2023, setting the foundation for the development and adoption of biosimilars, led by the U.S. and Canada. Very strong regulatory framework with approval from many of the biosimilars in the U.S. However, despite a few challenges related to patent disputes, reimbursement complexity, and physician/patient hesitation, the growth in the market is slow. Despite this, the region has remained a significant player in the biosimilars market as efforts are being continued to eradicate such barriers and to spur wider acceptance.
Conversely, the Asia-Pacific region encompassing countries like China, India, South Korea, and Japan would likely be a significant growth opportunity for biosimilars. These countries have growing healthcare requirements, increasing prevalence of chronic diseases, and the need for more and more cost-effective biologic therapies. The regional regulatory framework is undergoing a transformation where the central theme of standardization is propelling this change, making the acceptance process faster and upgrading local manufacturing skills. Large patient populations, the huge expenditure on health care, and government initiatives to enhance access to biological therapies are the most significant drivers of the Asia-Pacific biosimilar market. Biosimilars will be an integral part of affordable healthcare solutions in these countries, and hence, the region is expected to have significant growth.
Do You Need any Customization Research on Biosimilars Market - Enquire Now
Key Players
Dr. Reddy’s Laboratories
Sandoz
Coherus Biosciences
Viatris
Bio-Thera Solutions
Reliance Life Sciences
Intas Pharma
Celltrion
Zydus Cadila
Lupin Pharma
Samsung Bioepis
Pfizer
Apobiologix
Amgen
Teva Pharmaceuticals
Fresenius Kabi
Biocon Ltd
Biocad and others.
Recent Development
In September 2024, the European Medicines Agency (EMA) announced that its Committee for Human Medicinal Products (CHMP) recommended the approval of eight new medicines, including two biosimilars for the treatment of age-related macular degeneration. Additionally, extended indications were granted for 12 other drugs, covering treatments for cancer, hemophilia, and meningococcus.
In September 2024, OPUVIZ, a biosimilar referencing Eylea1 (aflibercept), became Samsung Bioepis and Biogen's second ophthalmology biosimilar to receive a marketing authorization recommendation from the European Medicines Agency.
In May 2023, Boehringer Ingelheim obtained U.S. FDA approval for the Cyltezo Pen, a new autoinjector option for Cyltezo (adalimumab-album), which is an FDA-approved interchangeable biosimilar to Humira.
| Report Attributes | Details |
| Market Size in 2023 | US$ 29.51 Billion |
| Market Size by 2032 | US$ 108.8 Billion |
| CAGR | CAGR of 17.7% From 2024 to 2032 |
| Base Year | 2023 |
| Forecast Period | 2024-2032 |
| Historical Data | 2020-2022 |
| Report Scope & Coverage | Market Size, Segments Analysis, Competitive Landscape, Regional Analysis, DROC & SWOT Analysis, Forecast Outlook |
| Key Segments | • By Type (Human growth hormone, Erythropoietin, Monoclonal antibodies, Insulin, Granulocyte-Colony Stimulating Factor, Others) • By Application (Blood disorders, Oncology diseases, Chronic and autoimmune diseases, Others) |
| Regional Analysis/Coverage |
North America (USA, Canada, Mexico), Europe (Germany, UK, France, Italy, Spain, Netherlands, Rest of Europe), Asia-Pacific (Japan, South Korea, China, India, Australia, Rest of Asia-Pacific), The Middle East & Africa (Israel, UAE, South Africa, Rest of Middle East & Africa), Latin America (Brazil, Argentina, Rest of Latin America) |
| Company Profiles | Dr. Reddy’s Laboratories, Sandoz, Coherus Biosciences, Viatris, Bio-Thera Solutions, Reliance Life Sciences, Intas Pharma, Celltrion, Zydus Cadila, Lupin Pharma & Others |
| Key Drivers |
• Development and Launches in Biosimilars |
| Market Restraints |
• High Costs and Stringent Quality Requirements |
Ans: The Biosimilars market is to grow at 17.7% Over the Forecast Period 2024-2032.
Ans: The Biosimilars market is to Hit USD 127.92 Billion by 2032.
Ans: The major key players are Dr Reddy’s Laboratories, Eli Lilly and Company, Pfizer Inc., Intas Pharmaceutical Ltd, Biocon Ltd, Merck & Co. Inc., Amgen Inc., Teva Pharmaceutical Industries Limited, Kashiv BioSciences, reliance life sciences and others
Ans: The Biosimilars Market size was valued at USD 29.51 Billion in 2023
Ans: The U.S. Food and Drug Administration (FDA) has currently approved 41 biosimilars.
Table of Contents
1. Introduction
1.1 Market Definition
1.2 Scope (Inclusion and Exclusions)
1.3 Research Assumptions
2. Executive Summary
2.1 Market Overview
2.2 Regional Synopsis
2.3 Competitive Summary
3. Research Methodology
3.1 Top-Down Approach
3.2 Bottom-up Approach
3.3. Data Validation
3.4 Primary Interviews
4. Market Dynamics Impact Analysis
4.1 Market Driving Factors Analysis
4.1.2 Drivers
4.1.2 Restraints
4.1.3 Opportunities
4.1.4 Challenges
4.2 PESTLE Analysis
4.3 Porter’s Five Forces Model
5. Statistical Insights and Trends Reporting
5.1 Incidence and Prevalence (2023)
5.2 Prescription Trends, (2023), by Region
5.3 Drug Volume: Production and usage volumes of pharmaceuticals.
5.4 Healthcare Spending: Expenditure data by government, insurers, and out-of-pocket by patients.
6. Competitive Landscape
6.1 List of Major Companies, By Region
6.2 Market Share Analysis, By Region
6.3 Service Benchmarking
6.3.1 Service specifications and features
6.3.2 Pricing
6.4 Strategic Initiatives
6.4.1 Marketing and promotional activities
6.4.2 Distribution and Supply Chain Strategies
6.4.3 Expansion plans and new Service launches
6.4.4 Strategic partnerships and collaborations
6.5 Technological Advancements
6.6 Market Positioning and Branding
7. Biosimilars market Segmentation, by Type
Chapter Overview
7.2 Human growth hormone
7.2.1 Human Growth Hormone Market Trends Analysis (2020-2032)
7.2.2 Human Growth Hormone Market Size Estimates and Forecasts to 2032 (USD Million)
7.3 Erythropoietin
7.3.1 Erythropoietin Market Trends Analysis (2020-2032)
7.3.2 Erythropoietin Market Size Estimates and Forecasts to 2032 (USD Million)
7.4 Monoclonal antibodies
7.4.1 Monoclonal antibodies Market Trends Analysis (2020-2032)
7.4.2 Monoclonal Antibodies Market Size Estimates and Forecasts to 2032 (USD Million)
7.5 Insulin
7.5.1 Insulin Market Trends Analysis (2020-2032)
7.5.2 Insulin Market Size Estimates and Forecasts to 2032 (USD Million)
7.6 Granulocyte-Colony Stimulating Factor
7.6.1 Granulocyte-Colony Stimulating Factor Market Trends Analysis (2020-2032)
7.6.2 Granulocyte-Colony Stimulating Factor Market Size Estimates and Forecasts to 2032 (USD Million)
8. Biosimilars market Segmentation, by Application
Chapter Overview
8.2 Blood disorders
8.2.1 Blood Disorders Market Trends Analysis (2020-2032)
8.2.2 Blood Disorders Market Size Estimates and Forecasts to 2032 (USD Million)
8.3 Oncology diseases
8.3.1 Oncology Diseases Market Trends Analysis (2020-2032)
8.3.2 Oncology Diseases Market Size Estimates and Forecasts to 2032 (USD Million)
8.4 Chronic and autoimmune diseases
8.4.1 Chronic and autoimmune diseases Market Trends Analysis (2020-2032)
8.4.2 Chronic and autoimmune diseases Market Size Estimates and Forecasts to 2032 (USD Million)
9. Regional Analysis
9.1 Chapter Overview
9.2 North America
9.2.1 Trends Analysis
9.2.2 North America Biosimilars market Estimates and Forecasts, by Country (2020-2032) (USD Million)
9.2.3 North America Biosimilars market Estimates and Forecasts, by Type (2020-2032) (USD Million)
9.2.4 North America Biosimilars market Estimates and Forecasts, by Application (2020-2032) (USD Million)
9.2.5 USA
9.2.5.1 USA Biosimilars market Estimates and Forecasts, by Type (2020-2032) (USD Million)
9.2.5.2 USA Biosimilars market Estimates and Forecasts, by Application (2020-2032) (USD Million)
9.2.6 Canada
9.2.6.1 Canada Biosimilars market Estimates and Forecasts, by Type (2020-2032) (USD Million)
9.2.6.2 Canada Biosimilars market Estimates and Forecasts, by Application (2020-2032) (USD Million)
9.2.7 Mexico
9.2.7.1 Mexico Biosimilars market Estimates and Forecasts, by Type (2020-2032) (USD Million)
9.2.7.2 Mexico Biosimilars market Estimates and Forecasts, by Application (2020-2032) (USD Million)
9.3 Europe
9.3.1 Eastern Europe
9.3.1.1 Trends Analysis
9.3.1.2 Eastern Europe Biosimilars market Estimates and Forecasts, by Country (2020-2032) (USD Million)
9.3.1.3 Eastern Europe Biosimilars market Estimates and Forecasts, by Type (2020-2032) (USD Million)
9.3.1.4 Eastern Europe Biosimilars market Estimates and Forecasts, by Application (2020-2032) (USD Million)
9.3.1.5 Poland
9.3.1.5.1 Poland Biosimilars market Estimates and Forecasts, by Type (2020-2032) (USD Million)
9.3.1.5.2 Poland Biosimilars market Estimates and Forecasts, by Application (2020-2032) (USD Million)
9.3.1.6 Romania
9.3.1.6.1 Romania Biosimilars market Estimates and Forecasts, by Type (2020-2032) (USD Million)
9.3.1.6.2 Romania Biosimilars market Estimates and Forecasts, by Application (2020-2032) (USD Million)
9.3.1.7 Hungary
9.3.1.7.1 Hungary Biosimilars market Estimates and Forecasts, by Type (2020-2032) (USD Million)
9.3.1.7.2 Hungary Biosimilars market Estimates and Forecasts, by Application (2020-2032) (USD Million)
9.3.1.8 Turkey
9.3.1.8.1 Turkey Biosimilars market Estimates and Forecasts, by Type (2020-2032) (USD Million)
9.3.1.8.2 Turkey Biosimilars market Estimates and Forecasts, by Application (2020-2032) (USD Million)
9.3.1.9 Rest of Eastern Europe
9.3.1.9.1 Rest of Eastern Europe Biosimilars market Estimates and Forecasts, by Type (2020-2032) (USD Million)
9.3.1.9.2 Rest of Eastern Europe Biosimilars market Estimates and Forecasts, by Application (2020-2032) (USD Million)
9.3.2 Western Europe
9.3.2.1 Trends Analysis
9.3.2.2 Western Europe Biosimilars market Estimates and Forecasts, by Country (2020-2032) (USD Million)
9.3.2.3 Western Europe Biosimilars market Estimates and Forecasts, by Type (2020-2032) (USD Million)
9.3.2.4 Western Europe Biosimilars market Estimates and Forecasts, by Application (2020-2032) (USD Million)
9.3.2.5 Germany
9.3.2.5.1 Germany Biosimilars market Estimates and Forecasts, by Type (2020-2032) (USD Million)
9.3.2.5.2 Germany Biosimilars market Estimates and Forecasts, by Application (2020-2032) (USD Million)
9.3.2.6 France
9.3.2.6.1 France Biosimilars market Estimates and Forecasts, by Type (2020-2032) (USD Million)
9.3.2.6.2 France Biosimilars market Estimates and Forecasts, by Application (2020-2032) (USD Million)
9.3.2.7 UK
9.3.2.7.1 UK Biosimilars market Estimates and Forecasts, by Type (2020-2032) (USD Million)
9.3.2.7.2 UK Biosimilars market Estimates and Forecasts, by Application (2020-2032) (USD Million)
9.3.2.8 Italy
9.3.2.8.1 Italy Biosimilars market Estimates and Forecasts, by Type (2020-2032) (USD Million)
9.3.2.8.2 Italy Biosimilars market Estimates and Forecasts, by Application (2020-2032) (USD Million)
9.3.2.9 Spain
9.3.2.9.1 Spain Biosimilars market Estimates and Forecasts, by Type (2020-2032) (USD Million)
9.3.2.9.2 Spain Biosimilars market Estimates and Forecasts, by Application (2020-2032) (USD Million)
9.3.2.10 Netherlands
9.3.2.10.1 Netherlands Biosimilars market Estimates and Forecasts, by Type (2020-2032) (USD Million)
9.3.2.10.2 Netherlands Biosimilars market Estimates and Forecasts, by Application (2020-2032) (USD Million)
9.3.2.11 Switzerland
9.3.2.11.1 Switzerland Biosimilars market Estimates and Forecasts, by Type (2020-2032) (USD Million)
9.3.2.11.2 Switzerland Biosimilars market Estimates and Forecasts, by Application (2020-2032) (USD Million)
9.3.2.12 Austria
9.3.2.12.1 Austria Biosimilars market Estimates and Forecasts, by Type (2020-2032) (USD Million)
9.3.2.12.2 Austria Biosimilars market Estimates and Forecasts, by Application (2020-2032) (USD Million)
9.3.2.13 Rest of Western Europe
9.3.2.13.1 Rest of Western Europe Biosimilars market Estimates and Forecasts, by Type (2020-2032) (USD Million)
9.3.2.13.2 Rest of Western Europe Biosimilars market Estimates and Forecasts, by Application (2020-2032) (USD Million)
9.4 Asia Pacific
9.4.1 Trends Analysis
9.4.2 Asia Pacific Biosimilars market Estimates and Forecasts, by Country (2020-2032) (USD Million)
9.4.3 Asia Pacific Biosimilars market Estimates and Forecasts, by Type (2020-2032) (USD Million)
9.4.4 Asia Pacific Biosimilars market Estimates and Forecasts, by Application (2020-2032) (USD Million)
9.4.5 China
9.4.5.1 China Biosimilars market Estimates and Forecasts, by Type (2020-2032) (USD Million)
9.4.5.2 China Biosimilars market Estimates and Forecasts, by Application (2020-2032) (USD Million)
9.4.6 India
9.4.5.1 India Biosimilars market Estimates and Forecasts, by Type (2020-2032) (USD Million)
9.4.5.2 India Biosimilars market Estimates and Forecasts, by Application (2020-2032) (USD Million)
9.4.5 Japan
9.4.5.1 Japan Biosimilars market Estimates and Forecasts, by Type (2020-2032) (USD Million)
9.4.5.2 Japan Biosimilars market Estimates and Forecasts, by Application (2020-2032) (USD Million)
9.4.6 South Korea
9.4.6.1 South Korea Biosimilars market Estimates and Forecasts, by Type (2020-2032) (USD Million)
9.4.6.2 South Korea Biosimilars market Estimates and Forecasts, by Application (2020-2032) (USD Million)
9.4.7 Vietnam
9.4.7.1 Vietnam Biosimilars market Estimates and Forecasts, by Type (2020-2032) (USD Million)
9.2.7.2 Vietnam Biosimilars market Estimates and Forecasts, by Application (2020-2032) (USD Million)
9.4.8 Singapore
9.4.8.1 Singapore Biosimilars market Estimates and Forecasts, by Type (2020-2032) (USD Million)
9.4.8.2 Singapore Biosimilars market Estimates and Forecasts, by Application (2020-2032) (USD Million)
9.4.9 Australia
9.4.9.1 Australia Biosimilars market Estimates and Forecasts, by Type (2020-2032) (USD Million)
9.4.9.2 Australia Biosimilars market Estimates and Forecasts, by Application (2020-2032) (USD Million)
9.4.10 Rest of Asia Pacific
9.4.10.1 Rest of Asia Pacific Biosimilars market Estimates and Forecasts, by Type (2020-2032) (USD Million)
9.4.10.2 Rest of Asia Pacific Biosimilars market Estimates and Forecasts, by Application (2020-2032) (USD Million)
9.5 Middle East and Africa
9.5.1 Middle East
9.5.1.1 Trends Analysis
9.5.1.2 Middle East Biosimilars market Estimates and Forecasts, by Country (2020-2032) (USD Million)
9.5.1.3 Middle East Biosimilars market Estimates and Forecasts, by Type (2020-2032) (USD Million)
9.5.1.4 Middle East Biosimilars market Estimates and Forecasts, by Application (2020-2032) (USD Million)
9.5.1.5 UAE
9.5.1.5.1 UAE Biosimilars market Estimates and Forecasts, by Type (2020-2032) (USD Million)
9.5.1.5.2 UAE Biosimilars market Estimates and Forecasts, by Application (2020-2032) (USD Million)
9.5.1.6 Egypt
9.5.1.6.1 Egypt Biosimilars market Estimates and Forecasts, by Type (2020-2032) (USD Million)
9.5.1.6.2 Egypt Biosimilars market Estimates and Forecasts, by Application (2020-2032) (USD Million)
9.5.1.7 Saudi Arabia
9.5.1.7.1 Saudi Arabia Biosimilars market Estimates and Forecasts, by Type (2020-2032) (USD Million)
9.5.1.7.2 Saudi Arabia Biosimilars market Estimates and Forecasts, by Application (2020-2032) (USD Million)
9.5.1.8 Qatar
9.5.1.8.1 Qatar Biosimilars market Estimates and Forecasts, by Type (2020-2032) (USD Million)
9.5.1.8.2 Qatar Biosimilars market Estimates and Forecasts, by Application (2020-2032) (USD Million)
9.5.1.9 Rest of Middle East
9.5.1.9.1 Rest of Middle East Biosimilars market Estimates and Forecasts, by Type (2020-2032) (USD Million)
9.5.1.9.2 Rest of Middle East Biosimilars market Estimates and Forecasts, by Application (2020-2032) (USD Million)
9.5.2 Africa
9.5.2.1 Trends Analysis
9.5.2.2 Africa Biosimilars market Estimates and Forecasts, by Country (2020-2032) (USD Million)
9.5.2.3 Africa Biosimilars market Estimates and Forecasts, by Type (2020-2032) (USD Million)
9.5.2.4 Africa Biosimilars market Estimates and Forecasts, by Application (2020-2032) (USD Million)
9.5.2.5 South Africa
9.5.2.5.1 South Africa Biosimilars market Estimates and Forecasts, by Type (2020-2032) (USD Million)
9.5.2.5.2 South Africa Biosimilars market Estimates and Forecasts, by Application (2020-2032) (USD Million)
9.5.2.6 Nigeria
9.5.2.6.1 Nigeria Biosimilars market Estimates and Forecasts, by Type (2020-2032) (USD Million)
9.5.2.6.2 Nigeria Biosimilars market Estimates and Forecasts, by Application (2020-2032) (USD Million)
9.6 Latin America
9.6.1 Trends Analysis
9.6.2 Latin America Biosimilars market Estimates and Forecasts, by Country (2020-2032) (USD Million)
9.6.3 Latin America Biosimilars market Estimates and Forecasts, by Type (2020-2032) (USD Million)
9.6.4 Latin America Biosimilars market Estimates and Forecasts, by Application (2020-2032) (USD Million)
9.6.5 Brazil
9.6.5.1 Brazil Biosimilars market Estimates and Forecasts, by Type (2020-2032) (USD Million)
9.6.5.2 Brazil Biosimilars market Estimates and Forecasts, by Application (2020-2032) (USD Million)
9.6.6 Argentina
9.6.6.1 Argentina Biosimilars market Estimates and Forecasts, by Type (2020-2032) (USD Million)
9.6.6.2 Argentina Biosimilars market Estimates and Forecasts, by Application (2020-2032) (USD Million)
9.6.7 Colombia
9.6.7.1 Colombia Biosimilars market Estimates and Forecasts, by Type (2020-2032) (USD Million)
9.6.7.2 Colombia Biosimilars market Estimates and Forecasts, by Application (2020-2032) (USD Million)
9.6.8 Rest of Latin America
9.6.8.1 Rest of Latin America Biosimilars market Estimates and Forecasts, by Type (2020-2032) (USD Million)
9.6.8.2 Rest of Latin America Biosimilars market Estimates and Forecasts, by Application (2020-2032) (USD Million)
10. Company Profiles
10.1 Pfizer
10.1.1 Company Overview
10.1.2 Financial
10.1.3 Services/ Services Offered
110.1.4 SWOT Analysis
10.2 Celltrion
10.2.1 Company Overview
10.2.2 Financial
10.2.3 Services/ Services Offered
10.2.4 SWOT Analysis
10.3 Intas Pharma
10.3.1 Company Overview
10.3.2 Financial
10.3.3 Services/ Services Offered
10.3.4 SWOT Analysis
10.4 Reliance Life Sciences
10.4.1 Company Overview
10.4.2 Financial
10.4.3 Services/ Services Offered
10.4.4 SWOT Analysis
10.5 Bio-Thera Solutions
10.5.1 Company Overview
10.5.2 Financial
10.5.3 Services/ Services Offered
10.5.4 SWOT Analysis
10.6 Samsung Bioepis
10.6.1 Company Overview
10.6.2 Financial
10.6.3 Services/ Services Offered
10.6.4 SWOT Analysis
10.7 Teva Pharmaceuticals
10.7.1 Company Overview
10.7.2 Financial
10.7.3 Services/ Services Offered
10.7.4 SWOT Analysis
10.8 Fresenius Kabi
10.8.1 Company Overview
10.8.2 Financial
10.8.3 Services/ Services Offered
10.8.4 SWOT Analysis
10.9 Biocon Ltd
10.9.1 Company Overview
10.9.2 Financial
10.9.3 Services/ Services Offered
10.9.4 SWOT Analysis
10.10 Apobiologix
10.9.1 Company Overview
10.9.2 Financial
10.9.3 Services/ Services Offered
10.9.4 SWOT Analysis
11. Use Cases and Best Practices
12. Conclusion
An accurate research report requires proper strategizing as well as implementation. There are multiple factors involved in the completion of good and accurate research report and selecting the best methodology to compete the research is the toughest part. Since the research reports we provide play a crucial role in any company’s decision-making process, therefore we at SNS Insider always believe that we should choose the best method which gives us results closer to reality. This allows us to reach at a stage wherein we can provide our clients best and accurate investment to output ratio.
Each report that we prepare takes a timeframe of 350-400 business hours for production. Starting from the selection of titles through a couple of in-depth brain storming session to the final QC process before uploading our titles on our website we dedicate around 350 working hours. The titles are selected based on their current market cap and the foreseen CAGR and growth.
The 5 steps process:
Step 1: Secondary Research:
Secondary Research or Desk Research is as the name suggests is a research process wherein, we collect data through the readily available information. In this process we use various paid and unpaid databases which our team has access to and gather data through the same. This includes examining of listed companies’ annual reports, Journals, SEC filling etc. Apart from this our team has access to various associations across the globe across different industries. Lastly, we have exchange relationships with various university as well as individual libraries.
Step 2: Primary Research
When we talk about primary research, it is a type of study in which the researchers collect relevant data samples directly, rather than relying on previously collected data. This type of research is focused on gaining content specific facts that can be sued to solve specific problems. Since the collected data is fresh and first hand therefore it makes the study more accurate and genuine.
We at SNS Insider have divided Primary Research into 2 parts.
Part 1 wherein we interview the KOLs of major players as well as the upcoming ones across various geographic regions. This allows us to have their view over the market scenario and acts as an important tool to come closer to the accurate market numbers. As many as 45 paid and unpaid primary interviews are taken from both the demand and supply side of the industry to make sure we land at an accurate judgement and analysis of the market.
This step involves the triangulation of data wherein our team analyses the interview transcripts, online survey responses and observation of on filed participants. The below mentioned chart should give a better understanding of the part 1 of the primary interview.
Part 2: In this part of primary research the data collected via secondary research and the part 1 of the primary research is validated with the interviews from individual consultants and subject matter experts.
Consultants are those set of people who have at least 12 years of experience and expertise within the industry whereas Subject Matter Experts are those with at least 15 years of experience behind their back within the same space. The data with the help of two main processes i.e., FGDs (Focused Group Discussions) and IDs (Individual Discussions). This gives us a 3rd party nonbiased primary view of the market scenario making it a more dependable one while collation of the data pointers.
Step 3: Data Bank Validation
Once all the information is collected via primary and secondary sources, we run that information for data validation. At our intelligence centre our research heads track a lot of information related to the market which includes the quarterly reports, the daily stock prices, and other relevant information. Our data bank server gets updated every fortnight and that is how the information which we collected using our primary and secondary information is revalidated in real time.
Step 4: QA/QC Process
After all the data collection and validation our team does a final level of quality check and quality assurance to get rid of any unwanted or undesired mistakes. This might include but not limited to getting rid of the any typos, duplication of numbers or missing of any important information. The people involved in this process include technical content writers, research heads and graphics people. Once this process is completed the title gets uploader on our platform for our clients to read it.
Step 5: Final QC/QA Process:
This is the last process and comes when the client has ordered the study. In this process a final QA/QC is done before the study is emailed to the client. Since we believe in giving our clients a good experience of our research studies, therefore, to make sure that we do not lack at our end in any way humanly possible we do a final round of quality check and then dispatch the study to the client.
Key Market Segmentation
By Type
Human growth hormone
Erythropoietin
Monoclonal antibodies
Insulin
Granulocyte-Colony Stimulating Factor
By Application
Blood disorders
Oncology diseases
Chronic and autoimmune diseases
Request for Segment Customization as per your Business Requirement: Segment Customization Request
Regional Coverage:
North America
US
Canada
Mexico
Europe
Eastern Europe
Poland
Romania
Hungary
Turkey
Rest of Eastern Europe
Western Europe
Germany
France
UK
Italy
Spain
Netherlands
Switzerland
Austria
Rest of Western Europe
Asia Pacific
China
India
Japan
South Korea
Vietnam
Singapore
Australia
Rest of Asia Pacific
Middle East & Africa
Middle East
UAE
Egypt
Saudi Arabia
Qatar
Rest of the Middle East
Africa
Nigeria
South Africa
Rest of Africa
Latin America
Brazil
Argentina
Colombia
Rest of Latin America
Request for Country Level Research Report: Country Level Customization Request
Available Customization
With the given market data, SNS Insider offers customization as per the company’s specific needs. The following customization options are available for the report:
Product Analysis
Criss-Cross segment analysis (e.g. Product X Application)
Product Matrix which gives a detailed comparison of the product portfolio of each company
Geographic Analysis
Additional countries in any of the regions
Company Information
Detailed analysis and profiling of additional market players (Up to five)
The High Throughput Screening Market Size was valued at USD 25.80 billion in 2023 and is witnessed to reach USD 69.46 Billion by 2032 and grow at a CAGR of 12.18% over the forecast period 2024-2032.
The Smoke Evacuation System Market Size, valued at USD 171.8 Million in 2023, is expected to reach USD 309.1 Million by 2032 at a CAGR of 6.7%.
The Hospital Information System Market Size was valued at USD 114.89 billion in 2023 and is expected to reach USD 484.50 billion by 2032 and grow at a CAGR of 17.34% over the forecast period 2024-2032.
The Mammography Workstations Market Size was valued at USD 152.75 million in 2023, and is expected to reach USD 264.42 million by 2031, and grow at a CAGR of 7.1% over the forecast period 2024-2031.
The Digital Twins in Healthcare Market size was valued at USD 1.41 billion in 2023, and is expected to reach USD 28.88 billion by 2032, and grow at a CAGR of 40.01% over the forecast period 2024-2032.
The Computed Tomography Market was worth USD 5.79 billion in 2023 and is predicted to be worth USD 10.70 billion by 2032, growing at a CAGR of 7.13% between 2024 and 2032.
Hi! Click one of our member below to chat on Phone
© 2024 All Rights Reserved by SNS Insider Pvt Ltd
